A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? | Oncotarget
Finding Targets in Cancer's Metabolic Quirks
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling | Journal of Experimental & Clinical Cancer Research | Full Text
Pharmacologic treatment with CPI-613 and PS48 decreases mitochondrial membrane potential and increases quantity of autolysosomes in porcine fibroblasts | Scientific Reports
Selectively Targeting Metabolism in Mitochondria In Cancer Cells | Cancer Biology
Cancers | Free Full-Text | The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Devimistat - Wikipedia
CPI-613 Supplier | CAS 95809-78-2 | Focus Biomolecules
The Mitochondrion as an Emerging Therapeutic Target in Cancer: Trends in Molecular Medicine
ラファエルホールディングスの適時開示・その他 | 米国株｜株探（かぶたん) - 株探
Frontiers | Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio | Oncology
Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study | Future Oncology
The Pyruvate Dehydrogenase Complex in Cancer: Implications for the Transformed State and Cancer Chemotherapy | IntechOpen
CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling | Journal of Experimental & Clinical Cancer Research | Full Text
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. - Abstract - Europe PMC
Cornerstone Pharmaceuticals Lead Compound CPI-613
Prolongation of survival induced by four doses of CPI-613 (25 mg/kg),... | Download Scientific Diagram
An integrated in vivo and in silico analysis of the metabolism disrupting effects of CPI-613 on embryo-larval zebrafish (Danio rerio) - ScienceDirect
Rafael Holdings, Inc. 2021 Current Report 8-K
Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation | Scientific Reports
A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process | SpringerLink
CPI-613 | CAS:95809-78-2 | PDH/α-KGDH inhibitor | High Purity | Manufacturer BioCrick
CPI-613 (Devimistat) | ≥99%(HPLC) | Dehydrogenase Inhibitor | AdooQ®
Mitochondrial Matrix Protease ClpP Agonists inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis | bioRxiv
CPI-613 induces reactive oxygen species-mediated glutathionylation and... | Download Scientific Diagram
